Why Satsuma Pharmaceuticals Stock Is Plummeting Today
Shares of Satsuma Pharmaceuticals (NASDAQ: STSA) are plunging today, down 74.8% as of 11:17 a.m. EDT, after the company announced that investigational drug STS101 failed to meet the primary endpoints in a phase 3 study in treating migraine.
Neither the 3.9 mg nor the 5.2 mg dose of the nasal powder achieved statistically significant improvement in the key symptoms of migraine at two hours after administration. Satsuma CEO John Kollins said that the company was "surprised and disappointed" by these results.
Image source: Getty Images.
Source Fool.com